Compare JBI & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBI | SGP |
|---|---|---|
| Founded | 2002 | 2019 |
| Country | United States | United States |
| Employees | N/A | 65 |
| Industry | Building Products | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 728.3M | 650.9M |
| IPO Year | 2021 | N/A |
| Metric | JBI | SGP |
|---|---|---|
| Price | $5.31 | $20.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $9.17 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 1.2M | 170.0K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.36 | N/A |
| Revenue Next Year | $3.16 | N/A |
| P/E Ratio | $12.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.26 | $17.06 |
| 52 Week High | $10.80 | $30.56 |
| Indicator | JBI | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 49.52 | 52.74 |
| Support Level | $4.89 | $17.74 |
| Resistance Level | $5.50 | $22.86 |
| Average True Range (ATR) | 0.15 | 1.74 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 58.47 | 45.75 |
Janus International Group Inc is a manufacturer and supplier of turnkey solutions for self-storage, commercial, and industrial building Solutions. It provides products that include roll-up and swing doors, hallway systems, relocatable storage MASS (Moveable Additional Storage Structures) units, and technologies for automating facility and door operation. It is operated through two geographic regions; Janus North America and Janus International. The Janus International segment is comprised of a subsidiary whose production and sales are largely in Europe and Australia. The Janus North America segment is comprised of all the other entities.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.